Pirtobrutinib, venetoclax, and rituximab for Waldenstrom's macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with Waldenstrom's macroglobulinemia or lymphoplasmacytic lymphoma and have not received any treatment for it
- You have signs that you need treatment, such as anemia, nerve problems, or symptoms from thick blood
- You can swallow pills
- You have adequate kidney, liver, and blood cell function (your doctor will check this)
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 1 year after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
This trial tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) for people with Waldenstrom's macroglobulinemia (a rare blood cancer) who have not yet had treatment. It aims to see if the combination is safe and effective.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.